Medical Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new treatment, supplement, or medication. Individual responses to therapies vary, and the information presented here should not replace the clinical judgment of your physician.

Integrating Low-Dose Naltrexone and Methylene Blue in Clinical Practice

Yoon Hang Kim, MD, MPH

Board Certified, Preventive Medicine | Board Certified, Integrative & Holistic Medicine

Medical Acupuncture (UCLA) | Osher Fellowship (University of Arizona)

www.directintegrativecare.com

Introduction

One of the most frequent questions I encounter in clinical practice is whether low-dose naltrexone (LDN) can worsen anxiety. The short answer is yes—it can happen, though the mechanism is more nuanced than a simple side effect. This question opens the door to a much broader conversation about the interplay between endorphins, emotional distress, neuropathic pain, chronic fatigue, and mitochondrial function. In this article, I will walk through the clinical reasoning I use when patients present with overlapping symptoms of pain, anxiety, fatigue, and nervous system dysregulation, and discuss how newer tools like methylene blue may complement LDN in ways that were not available to us even a few years ago.

LDN and the Anxiety Paradox: Endorphin Dynamics in Practice

LDN works by transiently blocking opioid receptors, which stimulates the body to upregulate endogenous opioid production—including beta-endorphin and met-enkephalin [1, 2]. This biofeedback mechanism is central to its therapeutic effects across autoimmune, pain, and neuropsychiatric conditions [3]. However, during the initial phase of treatment, there is a period of relative endorphin depletion while the body adjusts. In individuals who already rely on endogenous opioids to buffer anxiety or chronic pain, this temporary dip can unmask or amplify symptoms.

The body is remarkably adaptive in its use of available neurotransmitters. If endorphins, serotonin, or dopamine are present in sufficient quantities, the brain recruits them to stabilize mood and modulate the stress response. When one system is perturbed—as LDN temporarily does to the opioid system—symptoms that were previously managed may surface. This is why a patient whose chronic pain improves on LDN may simultaneously notice worsening anxiety: the endorphin rebound that reduces pain may not yet be sufficient to compensate for mood regulation needs.

Research supports this bidirectional relationship. A 2022 study on patients with multiple sclerosis found that LDN at standard doses (2.5–4 mg/day) was associated with reduced anxiety during the COVID-19 pandemic, likely through enhanced endorphin signaling [2]. Conversely, clinical reports and pharmacologic literature confirm that opioid receptor blockade—even at low doses—can transiently increase mood disturbance in susceptible individuals [4, 5]. The clinical takeaway is that dose sensitivity matters, and starting low with gradual titration remains essential.

Beyond Anxiety: Emotional Distress as a Clinical Construct

In practice, what patients label as “anxiety” is often a composite of anxiety and depression that is more accurately described as emotional distress. This distinction has therapeutic implications. I have observed this pattern in my own experience with ketogenic diets: entering ketosis substantially reduced my anxiety, likely through enhanced GABAergic transmission and reduced neuronal excitability [6, 7]. However, once the anxiety resolved, an underlying depressive tone became more apparent. Ketosis appears to have strong anxiolytic potential—mediated through GABA modulation, gut-brain axis effects, and reduced neuroinflammation—but it does not necessarily address the full spectrum of mood dysregulation [8, 9].

This experience reshaped my clinical approach. When treating patients with overlapping anxiety and depression, I consider that resolving one symptom may reveal the other. This is not a treatment failure—it is diagnostic information. It means the therapeutic plan needs additional layers, whether pharmacologic, nutritional, or behavioral.

LDN for Neuropathy: Dose-Dependent Responses

LDN has demonstrated efficacy for neuropathic pain in both clinical trials and retrospective analyses. A randomized, double-blind crossover trial comparing LDN (2 mg) to amitriptyline in painful diabetic neuropathy found similar analgesic efficacy but a superior safety profile for LDN [10]. A case series from a major pain center found that patients with neuropathic pain, including complex regional pain syndrome, were significantly more likely to respond to LDN than patients with mechanical pain conditions such as spondylosis [11]. LDN’s mechanism in neuropathy likely involves both TLR4-mediated microglial modulation and upstream endorphin enhancement [12].

A clinical scenario illustrates the nuances of dosing: a patient may experience substantial neuropathy improvement at 0.5 mg of LDN within two weeks, but upon titrating to 0.75 mg, develop symptoms of nervous system overstimulation—heightened sound sensitivity, internal restlessness, and physical manifestations of anxiety. This raises an important question: is the optimal dose for pain different from the dose needed to address fatigue or anxiety? In my experience, the answer is frequently yes. Pain management with LDN is often relatively straightforward, while fatigue and mood dysregulation require a broader, multimodal approach.

Chronic Fatigue Syndrome: Why LDN Is Necessary but Not Sufficient

For neuropathic pain, LDN may be both necessary and sufficient for clinical improvement. Chronic fatigue syndrome, however, is a different challenge. CFS is multifactorial by nature, and LDN—while often a critical starting point—is rarely the complete solution. I find it helpful to frame this with Dr. Jacob Teitelbaum’s S.H.I.N.E. model, which evaluates Sleep, Hormones, Infections/Immunity, Nutrition, and Exercise [13, 14]. Each of these domains may harbor a contributing cause that LDN alone cannot address.

LDN contributes to the SHINE framework by modulating immune function, reducing neuroinflammation, and supporting endorphin tone—addressing aspects of the Infections/Immunity, Sleep, and Hormones pillars. But if a patient has occult thyroid dysfunction, chronic sleep fragmentation, or nutritional deficiencies driving mitochondrial impairment, LDN alone will not produce full resolution. This is the distinction between necessary and sufficient: LDN starts the process, but additional interventions are typically required to close the therapeutic gap.

Methylene Blue: Mitochondrial Support and Beyond

After decades spent learning to fully utilize LDN, I have spent the past couple of years studying methylene blue (MB) as a complementary tool. The pharmacology is compelling: MB functions as an alternative electron carrier in the mitochondrial electron transport chain, shuttling electrons from NADH directly to cytochrome c and bypassing dysfunctional Complex I and Complex III [15, 16]. This rerouting enhances Complex IV activity, increases ATP production, and reduces mitochondrial reactive oxygen species (ROS) generation—a mechanism that has been well characterized in both in vitro and in vivo models of neurodegeneration [17, 18].

At low doses, MB primarily supports mitochondrial bioenergetics, which can manifest clinically as improved energy, cognitive clarity, and reduced fatigue. At higher doses, additional pharmacologic properties emerge, including antimicrobial activity (MB has been used to treat malaria since the 19th century) and effects on monoamine metabolism [15, 19]. MB is a potent reversible inhibitor of monoamine oxidase A (MAO-A), which increases synaptic availability of serotonin, norepinephrine, and dopamine [19]. This dual action—mitochondrial support combined with monoaminergic modulation—makes MB a versatile tool, particularly in patients with fatigue-predominant presentations.

When paired with LDN’s immune-modulating and endorphin-enhancing effects, MB offers a complementary mechanism that targets the cellular energy deficit underlying many chronic conditions. Together, these approaches address different layers of the same problem—LDN addressing neuroimmune dysregulation from the top down, and MB supporting mitochondrial function from the bottom up.

Safety Considerations: Methylene Blue and Serotonin Toxicity

The primary safety concern with methylene blue involves its interaction with serotonergic medications. Because MB inhibits MAO-A, concurrent use with SSRIs, SNRIs, or clomipramine carries a risk of serotonin toxicity [19, 20, 21]. The FDA has issued specific guidance on this interaction, noting that reported cases involved intravenous administration in patients already taking serotonin reuptake inhibitors [22].

Importantly, the context matters. The overwhelming majority of serotonin toxicity cases in the literature involve parenteral (intravenous) MB at doses of 1–2 mg/kg or higher, typically administered during surgical procedures [20, 21, 23]. Oral MB behaves differently pharmacokinetically—absorption is slower, peak concentrations are lower, and first-pass metabolism modifies its bioavailability. A comprehensive review of the literature found that nearly all reported cases of MB-induced serotonin syndrome involved IV administration, with only a single case report potentially linked to oral use [24]. Nevertheless, caution is warranted, and concurrent use with serotonergic medications should be approached conservatively and on an individualized basis.

At typical oral doses, the most commonly noticed effect is blue-green discoloration of urine, which simply reflects excretion of excess dye and is not clinically significant. The key clinical principle is to follow symptoms rather than adhere to a rigid dosing rule, and to titrate based on individual response.

Lifestyle Practices: The Non-Pharmacologic Foundation

No pharmacologic strategy for anxiety or fatigue is complete without attention to lifestyle practices. In my clinical experience, several approaches deserve emphasis. Prayer, meditation, and structured breathing exercises activate the parasympathetic nervous system and can meaningfully shift the balance away from chronic sympathetic overdrive. Expressive writing—simply writing down worries and fears—has a documented evidence base for reducing rumination and perceived stress intensity. Once thoughts are externalized on paper, they often lose their subjective intensity and become more manageable.

Physical movement, even modest activity, supports mitochondrial biogenesis, endorphin release, and neurotransmitter balance. I have personally found value in returning to martial arts movements I practiced when younger—simple katas and kicks that engage both body and mind. Managing complex chronic conditions can feel like a full-time job, and incorporating enjoyable physical activity helps sustain the psychological resilience needed for the long-term work of healing.

Technology can also play a supporting role. AI tools and digital platforms can assist patients with organizing health information, structuring reflective journaling, and approaching stressful situations from multiple perspectives. While not a replacement for human connection and professional guidance, these tools can help patients build self-awareness between clinical visits.

Conclusion

The intersection of LDN, emotional distress, neuropathy, chronic fatigue, and mitochondrial support requires a layered clinical approach. LDN remains a foundational tool—effective for neuropathic pain and a valuable starting point for chronic fatigue—but it is rarely the entire answer. Understanding that anxiety and depression often coexist as emotional distress, that dose-dependent responses require careful titration, and that mitochondrial dysfunction may underlie persistent fatigue all inform a more complete treatment strategy. Methylene blue offers a compelling complementary mechanism by addressing the cellular energy deficit that LDN cannot directly reach. Together with lifestyle practices, the SHINE framework, and individualized clinical reasoning, these tools represent a meaningful expansion of what we can offer patients navigating complex, overlapping chronic conditions.

References

1. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671-673.

2. Patel CL, Thomas GA, Engel CE, et al. Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic. Mult Scler Relat Disord. 2023;69:104412. doi:10.1016/j.msard.2022.104412

3. Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72(3):333-337. doi:10.1016/j.mehy.2008.06.048

4. Mischoulon D, Hylek L, Yeung AS, et al. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6-14. doi:10.1016/j.jad.2016.08.029

5. Bolton MJ, Chapman BP, Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13(1):e232502. doi:10.1136/bcr-2019-232502

6. Calderón N, Betancourt L, Hernández L, Rada P. A ketogenic diet modifies glutamate, gamma-aminobutyric acid and agmatine levels in the hippocampus of rats: A microdialysis study. Neurosci Lett. 2017;642:158-162.

7. Puchowicz MA, Xu K, Sun X, et al. Diet-induced ketosis increases capillary density without altered blood flow in rat brain. Am J Physiol Endocrinol Metab. 2007;292(6):E1607-E1615.

8. Norwitz NG, Dalai SS, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020;27(5):269-274.

9. Brietzke E, Mansur RB, Subramaniapillai M, et al. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Neurosci Biobehav Rev. 2018;94:11-16. doi:10.1016/j.neubiorev.2018.07.020

10. Srinivasan A, Dutta P, Bansal R, Narang T, Gudala K. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770-778. doi:10.1111/1753-0407.13202

11. Dieckmann G, Ozmen MC, Cox SM, Engber S, Bhatt P, Bhatt P. Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series. J Pain Res. 2023;16:2067-2076. doi:10.2147/JPR.S408aborandoS

12. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. doi:10.1007/s10067-014-2517-2

13. Teitelbaum JE, Bird B, Greenfield RM, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome and fibromyalgia: a randomized, double-blind, placebo-controlled, intent-to-treat study. J Chronic Fatigue Syndr. 2001;8(2):3-28. doi:10.1300/J092v08n02_02

14. Teitelbaum J. From Fatigued to Fantastic! 4th ed. Avery Publishing; 2020.

15. Yang SH, Li W, Sumien N, Forster M, Simpkins JW, Liu R. Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: methylene blue connects the dots. Prog Neurobiol. 2017;157:273-291. doi:10.1016/j.pneurobio.2015.10.005

16. Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection—an emerging role for methylene blue. Mol Neurobiol. 2018;55(6):5137-5153. doi:10.1007/s12035-017-0712-2

17. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32-45. doi:10.1016/j.pneurobio.2011.10.007

18. Xiong ZM, O'Donovan M, Sun L, Choi JY, Bhanu M, Bhanu N. The potentials of methylene blue as an anti-aging drug. Cells. 2021;10(12):3379. doi:10.3390/cells10123379

19. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;152(6):946-951. doi:10.1038/sj.bjp.0707430

20. Ng BK, Cameron AJ. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics. 2010;51(3):194-200. doi:10.1016/S0033-3182(10)70685-X

21. Gillman PK. Methylene blue and serotonin toxicity: definite causal link. Psychosomatics. 2010;51(5):448-449. doi:10.1176/appi.psy.51.5.448

22. U.S. Food and Drug Administration. FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications. October 2011. Available at: https://www.fda.gov/drugs/drug-safety-and-availability

23. Top WM, Gillman PK, de Langen CJ, Kooy A. Fatal methylene blue associated serotonin toxicity. Neth J Med. 2014;72(3):179-181.

24. Fagron Academy. Methylene blue: understanding drug interactions. Available at: https://www.fagronacademy.us/blog/methylene-blue-understanding-drug-interactions. Accessed 2025.

© 2026 Yoon Hang Kim, MD, MPH | Direct Integrative Care | www.directintegrativecare.com